PPMD is deeply disappointed that Dr. Peter Marks has made the decision to leave his role as Director of the FDA’s Center for Biologics Evaluation and Research (CBER). Dr. Marks has been an extraordinary public servant and a steadfast advocate, and we are deeply grateful for his years of service. PPMD remains steadfast in our commitment to protecting and advancing the progress we’ve fought so hard to achieve, and we will work closely with regulatory experts, policymakers, and partners to understand the full implications of this personnel change. Learn more: https://lnkd.in/eBpgzSeU
